Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma.
http://www.benzinga.com/news/13/06/3672784/verastem-wins-orphan-medicinal-product-designation-from-ec-for-vs-6063
http://www.benzinga.com/news/13/06/3672784/verastem-wins-orphan-medicinal-product-designation-from-ec-for-vs-6063
No comments:
Post a Comment